INDIA GLYCOLS LIMITED

DNV
ISO 9001, ISO 14001, ISO 45001, ISO 50001

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/2026-27/76

13th November, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 500201

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Outcome of the Board Meeting held on 13th November, 2026

Further to our letter no. IGL/SE/2026-27/74 dated 6th November, 2026 and pursuant to Regulation 30 and Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e. 13th November, 2026 has, inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2026.

A copy of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2026 along with the Limited Review Report of Statutory Auditors thereon are enclosed herewith.

The above said Board Meeting commenced at 16:18 Hrs. and concluded at 17:15 Hrs.

This is for your information and record.

Thanking you,

Yours truly,
For India Glycols Limited
ANKU R JAIN
Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a

INDIA GLYCOLS LIMITED
Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand)
Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535
Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com
CIN No.L24111UR1983PLC009097

Statement Of Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2026

(₹ In Crores, except as stated)

S.No	Particulars	Standalone					
		Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income from operations**						
	(a) Revenue from operations	358.18	354.64	2,410.71	712.82	4,913.74	9,826.20
	(b) Other income	0.33	0.37	2.17	0.70	3.57	43.51
	Total income	358.51	355.01	2,412.88	713.52	4,917.31	9,869.71
2	**Expenses**						
	(a) Cost of materials consumed	172.47	245.44	660.85	417.91	1,329.95	2,412.43
	(b) Purchase of stock-in-trade	-	-	63.21	-	107.40	188.46
	(c) Changes in inventories of finished goods, Stock-in Trade and work-in-progress	53.42	(18.48)	(39.69)	34.94	(75.66)	60.92
	(d) Excise Duty	-	-	-	-	-	-
	(e) Employee benefits expense	16.43	19.04	1,320.20	-	2,782.86	5,615.22
	(f) Finance Costs	12.07	11.64	31.64	35.47	62.24	130.69
	(g) Depreciation and amortisation expense	12.02	12.03	49.28	23.71	93.96	167.18
	(h) Power and fuel	44.33	40.22	38.48	24.05	72.93	155.38
	(i) Other Expenses	32.52	28.58	115.49	84.55	207.02	400.50
	Total Expenses	343.26	338.47	100.93	61.10	193.99	371.40
	Profit Before Interest, Depreciation and Tax (EBIDTA)	39.34	40.21	2,340.39	681.73	4,774.69	9,502.18
3	**Profit / (Loss) from operations before exceptional items and tax (1-2)**	15.25	16.54	160.25	79.55	309.51	690.09
4	Exceptional Items	-	-	72.49	31.79	142.62	367.53
5	**Profit / (Loss) before Tax (3-4)**	15.25	16.54	-	-	-	0.83
6	Tax expense :			72.49	31.79	142.62	366.70
	(a) Current Tax	1.89	2.13	9.72	4.02	17.29	21.07
	(b) Deferred Tax	2.12	2.06	8.83	4.18	18.54	63.30
7	**Profit / (Loss) for the period (5-6)**	11.24	12.35	53.94	23.59	106.79	282.33
8	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or Loss	(0.14)	(0.14)	(0.25)	(0.28)	(0.50)	(2.27)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	0.04	0.03	0.07	0.07	0.13	0.57
	B (i) Items that will be reclassified to Profit or Loss	-	-	-			-
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-			-
	Other Comprehensive Income (Net of Tax)	(0.10)	(0.11)	(0.18)	(0.21)	(0.37)	(1.70)
9	**Total comprehensive income / (loss) for the period (7+8)**	11.14	12.24	53.76	23.38	106.42	280.63
10	Paid-up Equity Share Capital (Face value Rs. 5/- each)	33.51	33.51	30.96	33.51	30.96	33.51
11	Other Equity						2,503.93
12	**Earning per equity share (face value of Rs 5/- each) Not annualised (In Rs.)**						
	- Basic	1.68	1.84	8.71	3.52	17.25	44.31
	- Diluted	1.68	1.84	8.71	3.52	17.25	44.31

(₹ In Crores)

S.No	Unaudited Standalone Segment wise Revenue, Results and Assets and Liabili / Particulars	Standalone					
		Quarter ended			Half Year ended		Year Ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Segment Revenue**						
	- Bio-based Specialities and Performance Chemicals	358.18	354.64	286.64	712.82	586.54	1,202.07
	- Potable Spirits	-	-	1,657.82	-	3,462.88	6,946.43
	- Ennature Biopharma	-	-	43.44	-	93.94	207.77
	- Bio-Fuel	-	-	422.81	-	770.38	1,469.93
	Total	358.18	354.64	2,410.71	712.82	4,913.74	9,826.20

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

2	Segment Results (Profit / (Loss) before Interest and Tax)						
	- Bio-based Specialities and Performance Chemicals	27.32	28.18	31.85	55.50	62.67	138.27
	- Potable Spirits	-	-	72.39	-	144.72	284.93
	- Ennature Biopharma	-	-	0.98	-	2.18	7.23
	- Bio-Fuel	-	-	29.36	-	52.03	115.23
	Total	**27.32**	**28.18**	**134.58**	**55.50**	**261.60**	**545.66**
	Less :						
	- Interest (Net)	12.07	11.64	49.28	23.71	93.96	167.18
	- Exceptional Items			-		-	0.83
	- Unallocated corporate expenses net of unallocable income	-	-	12.81	-	25.02	10.95
	Profit Before Tax	**15.25**	**16.54**	**72.49**	**31.79**	**142.62**	**366.70**
3	**Segment assets**						
	- Bio-based Specialities and Performance Chemicals	2,181.53	2,092.23	3,343.24	2,181.53	3,343.24	3,595.99
	- Potable Spirits	-	-	579.81	-	579.81	596.60
	- Ennature Biopharma	-	-	441.38	-	441.38	426.42
	- Bio-fuel	-	-	1,263.63	-	1,263.63	1,429.96
	- Unallocated	-	-	111.99	-	111.99	77.15
	Total	**2,181.53**	**2,092.23**	**5,740.05**	**2,181.53**	**5,740.05**	**6,126.12**
4	**Segment liabilities**						
	- Bio-based Specialities and Performance Chemicals	1,351.98	1,273.81	687.54	1,351.98	687.54	737.05
	- Potable Spirits	-	-	290.43	-	290.43	326.53
	- Ennature Biopharma	-	-	77.90	-	77.90	92.49
	- Bio-fuel	-	-	82.42	-	82.42	92.27
	- Unallocated	-	-	2,624.31	-	2,624.31	2,340.34
	Total	**1,351.98**	**1,273.81**	**3,762.60**	**1,351.98**	**3,762.60**	**3,588.68**

Notes:

1 The above results were reviewed by the Audit committee in its meeting held on November 13, 2026 and have been approved by the Board of Directors in its meeting held on November 13, 2026. The auditors of the Company have carried out a limited review of the same.

2 Financial results have been prepared and presented in accordance with the recognition and measurement principles prescribed under Section 133 of the Companies Act, 2013.

3 The Hon'ble National Company Law Tribunal, Allahabad Bench, Prayagraj ("NCLT"), vide its order dated July 17, 2026, has approved the Scheme of Arrangement ("Scheme") among India Glycols Limited (Demerged Company) and IGL Spirits Limited (Resulting Company 1) and Ennature Bio Pharma Limited (Resulting Company 2) and their respective shareholders and creditors for the demerger of the Spirits and Biofuel Undertaking and Biopharma Undertaking into IGL Spirits Limited and Ennature Bio Pharma Limited respectively. The Scheme became effective on September 01, 2026 with the appointed date 01st April 2026.
(i) Spirits and Biofuel undertaking and Biopharma Undertaking of India Glycols Limited has been demerged and vested in IGL Spirits Limited and Ennature Biopharma Limited respectively as a going concern w.e.f. the appointed date of April 1, 2026, as per the Scheme.
(ii) All the carrying value of assets, liabilities and identified reserves of the Spirits and Biofuel undertaking and Biopharma Undertaking have been transferred to the Resulting Companies. The difference between the value of transferred assets, liabilities and identified reserves pertaining to the Spirits and Biofuel undertaking and Biopharma Undertaking has been adjusted in the other equity as per the applicable laws.
(iii) Accordingly, the financial results of the Company for the quarter ended June 30, 2026 and the quarter and the six months ended September 30, 2026, do not include the financial performance of the Spirits and Biofuel undertaking and Biopharma Undertaking of the Company and restated the figures for the quarter ended 30th June 2026..
(iv) The comparative figures for the quarter and six months ended 30 September 2025 and the year ended 31 March 2026 include the Spirits and Biofuel Undertaking and Biopharma Undertaking, which have been demerged from the Company with effect from 1 April 2026 pursuant to the Scheme of Arrangement. Accordingly, such comparative figures are not comparable with the corresponding current-period figures/six months figures.
(v) All sales and purchases of Spirits & Biofuel and Biopharma businesses continue to be accounted in the books of account of India Glycols Limited but transferred to the respective resulting companies as provided in the aforesaid scheme approved.

4 The Company has identified its business operations as a single reportable segment, namely 'Bio-based Specialties and Performance Chemicals', in accordance with the requirements of Ind AS 108 – Operating Segments. Accordingly, no separate segment information has been provided for the current period.

6 The figures of the previous period/year have been restated/regrouped wherever necessary, to make them comparable.

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

For INDIA GLYCOLS LIMITED

U.S. BHARTIA
Chairman and Managing Director
DIN: 00063091

Place : Noida
Date : 13th November , 2026

Statement of Standalone Cash Flows

(₹ In Crores)

	Particulars	Standalone Half Year ended 30.09.2026 (Unaudited)	Standalone Half Year ended 30.09.2025 (Unaudited)
A.	**Cash Flow from Operating Activities**		
	Net Profit/(Loss) Before Tax	**31.79**	**142.62**
	Adjustments For:		
	Depreciation and amortisation expense	24.05	72.93
	(Profit)/Loss on Sale of Property, plant & equipment	(0.01)	(0.75)
	Net Unrealised Foreign Exchange Fluctuation (Gain) / Loss	(2.86)	8.31
	Govt Grant (net)	-	(0.06)
	Provision No Longer Required Written Back	(0.71)	(0.02)
	Finance Costs	23.71	94.23
	Interest Income	(0.70)	(2.86)
	Operating Profit/ (Loss) before Working Capital Changes	**75.27**	**314.40**
	Adjustments For:		
	(Increase)/Decrease in Trade & Other Receivables	(4.64)	61.22
	(Increase)/Decrease in Inventories	52.11	86.00
	Increase / (Decrease) in Trade & Other Payables	(72.41)	(343.11)
	Cash Generated from / (Used in) Operations	**50.33**	**118.51**
	Income Tax Paid (Net)	(10.45)	(12.59)
	Net Cash flow from / (Used in) Operating Activities	**39.88**	**105.92**
B.	**Cash Flow from Investing Activities**		
	Purchase of Property, plant & equipment	(95.23)	(165.11)
	Interest received	0.70	6.07
	Net Cash flow from / (Used in) Investing Activities	**(94.53)**	**(159.04)**
C.	**Cash Flow from Financing Activities**		
	'Proceeds/(Payment) from Borrowings	58.26	169.18
	Proceeds/(Payment) of lease liabilities	-	(9.90)
	Finance Costs Paid	(23.71)	(95.33)
	Dividends Paid	-	(0.23)
	Net Cash flow from / (Used in) Financing Activities	**34.55**	**63.72**
	Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	**(20.10)**	**10.60**
	Opening Cash & Cash Equivalents	**26.35**	**6.51**
	Closing Cash & Cash Equivalents	**6.25**	**17.11**

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard -7, "Statement of Cash Flows".

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

Statement of Standalone Assets and Liabilities

(₹ In Crores)

	Particulars	Standalone As At 30.09.2026 (Unaudited)	Standalone As At 31.03.2026 (Audited)
A.	**ASSETS**		
1	**Non-current Assets**		
	(a) Property, Plant and Equipment	1,254.43	4,445.21
	(b) Capital work-in-progress	113.52	36.70
	(c) Investment Property	1.70	1.72
	(d) Other Intangible assets	0.68	1.46
	(e) Right to use assets	-	106.08
	(f) Financial Assets	-	
	(i) Investments	0.02	0.04
	(ii) Loans	1.18	1.50
	(iii) Others	35.83	41.08
	(g) Other non-current assets	2.69	2.60
	Total Non Current Assets	1,410.05	4,636.39
2	**Current Assets**		
	(a) Inventories	550.82	887.99
	(b) Financial Assets	-	
	(i) Trade receivables	77.91	352.66
	(ii) Cash and cash equivalents	6.25	31.06
	(iii) Bank balances other than (ii) above	8.78	17.96
	(iv) Loans	20.42	20.42
	(v) Others	17.53	15.74
	(c) Current Tax Assets (Net)	18.29	11.86
	(d) Other current assets	71.48	152.04
	Total Current Assets	771.48	1,489.73
	Total Assets	**2,181.53**	**6,126.12**
B.	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	33.51	33.51
	(b) Other Equity	796.04	2,503.93
	Total Equity	829.55	2,537.44
2	**Liabilities**		
2.1	**Non-current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	341.48	919.13
	(ii) Lease Liabilities	-	81.13
	(iii) Other financial liabilities	-	62.29
	(b) Provisions	2.91	5.68
	(c) Deferred tax liabilities (Net)	151.17	505.11
	(d) Others	-	2.72
	Total Non-current Liabilities	495.56	1,576.06
2.2	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	484.49	659.34
	(ii) Lease Liabilities	-	31.01
	(iii) Trade payables	-	
	total outstanding dues of micro enterprises and small enterprises	-	0.17
	total outstanding dues of creditors other than micro enterprises and small enterprises	55.34	787.71
	(iv) Other financial liabilities	274.90	399.80
	(b) Other current liabilities	37.28	127.03
	(c) Provisions	4.41	7.56
	Total Current Liabilities	856.42	2,012.62
	Total Equity and Liabilities	**2,181.53**	**6,126.12**

Note : Assets & Liabilities as on 31 March 2026 include combined results of Spirits & Biofuel and Biopharma businesses.

K.K. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of India Glycols Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To The Board of Directors of India Glycols Limited

1. We have reviewed the accompanying statement of unaudited financial results (the 'Statement') of India Glycols Limited (the 'Company'), for the quarter ended 30th September 2026 and year to date results for the period 1st April 2026 to 30th September 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Listing Regulations"), as amended to date, which has been initialed by us for identification purpose.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, *"Interim Financial Reporting"* ("Ind As 34") prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to note 3 to the statement with respect to the Scheme of Arrangement ("Scheme") duly approved by the Hon'ble National Company Law Tribunal, Allahabad Bench, Prayagraj ("NCLT"). The Spirits and Biofuel undertaking and Biopharma undertaking of the Company stands demerged and vested in IGL Spirits Limited and Ennature Bio Pharma Limited respectively w.e.f. April 1, 2026, being the appointed date. Consequently, the results for the quarter ended June 30, 2026, which was subject to limited review by us as requiredunder the Listing Regulations, have been restated to give effect to the demerger. The demerger has been accounted w.e.f. appointed date April 1, 2026, in accordance with the



K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

accounting treatment specified in the Scheme. Further, IGL Spirits Limited and Ennature Bio Pharma Limited cease to be the subsidiary of the Company with effect from the appointed date.

Our conclusion is not modified in respect of this matter.

For **K N GUTGUTIA & CO.**
Chartered Accountants
Firm's Registration No. 304153E

(B.R. GOYAL)
Partner
Membership No. 012172
UDIN: 26012172EFCLRK5811

Date: 13th November 2026
Place of Signature: Noida

INDIA GLYCOLS LIMITED
Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand)
Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535
Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com
CIN No.L24111UR1983PLC009097

Statement Of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 (₹ In Crores, except as stated)

S.N	Particulars	Consolidated					
		Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income from operations**						
	(a) Revenue from operations	362.42	357.08	2,412.40	719.50	4,915.52	9,826.63
	(b) Other income	0.33	0.37	2.17	0.70	3.57	4.93
	Total Income	362.75	357.45	2,414.57	720.20	4,919.09	9,831.56
2	**Expenses**						
	(a) Cost of materials consumed	172.47	245.44	660.85	417.91	1,329.95	2,412.43
	(b) Purchase of stock-in-trade	3.65	2.11	63.25	5.76	107.59	187.22
	(c) Changes in inventories of finished goods, Stock-in Trade and work-in-progress	53.41	(18.47)	(38.25)	34.94	(74.22)	62.35
		-	-	-	-	-	-
	(d) Excise Duty	-	-	1,320.20	-	2,782.86	5,615.22
	(e) Employee benefits expense	16.95	19.55	32.11	36.50	63.17	132.61
	(f) Finance Costs	12.07	11.64	49.28	23.71	93.96	167.18
	(g) Depreciation and amortisation expense	12.01	12.04	38.48	24.05	72.93	155.38
	(h) Power and fuel	44.33	40.22	115.49	84.55	207.02	400.50
	(i) Other Expenses	32.80	28.74	101.11	61.54	191.87	367.05
	Total Expenses	347.69	341.27	2,342.52	688.96	4,775.13	9,499.94
	Profit Before Interest, Depreciation and Tax (EBIDTA)	39.14	39.86	159.81	79.00	310.85	654.18
3	**Profit / (Loss) from operations before exceptional Items and tax (1-2)**	**15.06**	**16.18**	**72.05**	**31.24**	**143.96**	**331.62**
4	Exceptional Items			-	-	-	0.83
5	**Profit / (Loss) before Tax (3-4)**	**15.06**	**16.18**	**72.05**	**31.24**	**143.96**	**330.79**
6	**Share of net profit/ (loss) of Joint Venture**	12.64	**20.60**	**11.56**	**33.24**	**30.18**	**46.42**
7	**Profit / (Loss) before Tax (5+6)**	**27.70**	**36.78**	**83.61**	**64.48**	**174.14**	**377.21**
8	Tax expense :						
	(a) Current Tax	1.89	2.13	9.72	4.02	17.29	21.15
	(b) Deferred Tax	2.12	2.06	8.83	4.18	18.54	63.30
9	**Profit / (Loss) after tax (7-8)**	**23.69**	**32.59**	**65.06**	**56.28**	**138.31**	**292.76**
10	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or Loss	0.01	(0.10)	(0.43)	(0.09)	(0.80)	(2.33)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	0.02	0.11	0.02	0.20	0.59
	B (i) Items that will be reclassified to Profit or Loss	0.03	0.01	0.18	0.04	0.03	0.12
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-			-
		-		-			
	Other Comprehensive Income (Net of Tax)	**0.04**	**(0.07)**	**(0.14)**	**(0.03)**	**(0.57)**	**(1.62)**
11	**Total comprehensive Income / (loss) for the period (9+10)**	**23.73**	**32.52**	**64.92**	**56.25**	**137.74**	**291.14**
12	**Net Profit/ (Loss) attributable to**						
	(a) Owners of the Company	23.69	32.59	65.06	56.28	138.31	292.76
	(b) Non Controlling interest	-	-	-			-
13	**Other Comprehensive Income attributable to**						
	(a) Owners of the Company	0.11	(0.14)	(0.14)	(0.03)	(0.57)	(1.62)
	(b) Non Controlling interest	-	-	-			
14	**Total Comprehensive Income attributable to**						
	(a) Owners of the Company	23.80	32.45	64.92	56.25	137.74	291.14
	(b) Non Controlling interest	-	-	-	-	-	-
15	Paid-up Equity Share Capital (Face value Rs. 5/- each)	33.51	33.51	30.96	33.51	30.96	33.51
16	Other Equity						2,899.27
17	**Earning per equity share (face value of Rs 5/- each) Not annualised (In Rs.)**						
	- Basic	3.53	4.86	10.51	8.40	22.34	45.95
	- Diluted	3.53	4.86	10.51	8.40	22.34	45.95

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

(₹ In Crores)

Consolidated Unaudited Segment wise Revenue, Results and Assets and Liabilities

S.N	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Segment Revenue**						
	- Bio-based Specialities and Performance Chemicals	362.42	357.08	288.33	719.50	588.32	1,202.50
	- Potable Spirits	-	-	1,657.82	-	3,462.88	6,946.43
	- Ennature Biopharma	-	-	43.44	-	93.94	207.77
	- Bio-Fuel	-	-	422.81	-	770.38	1,469.93
	Total	**362.42**	**357.08**	**2,412.40**	**719.50**	**4,915.52**	**9,826.63**
2	Segment Results (Profit / (Loss) before Interest and Tax)						
	- Bio-based Specialities and Performance Chemicals	27.13	27.82	31.41	54.95	64.01	140.95
	- Potable Spirits	-	-	72.39	-	144.72	284.93
	- Ennature Biopharma	-	-	0.98	-	2.18	7.23
	- Bio-Fuel	-	-	29.36	-	52.03	115.23
	Total	**27.13**	**27.82**	**134.14**	**54.95**	**262.94**	**548.34**
	Less :						
	- Interest (Net)	12.07	11.64	49.28	23.71	93.96	167.18
	- Exceptional Items	-	-	-		-	0.83
	- Unallocated corporate expenses net of unallocable income	-	-	12.81	-	25.02	49.54
	Profit before share of profit / (Loss) from joint venture and exceptional items	**15.06**	**16.18**	**72.05**	**31.24**	**143.96**	**330.79**
	Share of profit/(loss) of Joint Venture	12.64	20.60	11.56	33.24	30.18	46.42
	Profit Before Tax	**27.70**	**36.78**	**83.61**	**64.48**	**174.14**	**377.21**
3	**Segment assets**						
	- Bio-based Specialities and Performance Chemicals	2,611.02	2,508.90	3,346.21	2,611.02	3,346.21	3,600.59
	- Potable Spirits	-	-	579.81	-	579.81	596.60
	- Ennature Biopharma	-	-	441.38	-	441.38	426.42
	- Bio-Fuel	-	-	1,263.63	-	1,263.63	1,429.96
	- Unallocated	-	-	526.21	-	526.21	469.38
	Total	**2,611.02**	**2,508.90**	**6,157.24**	**2,611.02**	**6,157.24**	**6,522.95**
4	**Segment liabilities**						
	- Bio-based Specialities and Performance Chemicals	1,353.24	1,274.85	688.23	1,353.24	688.23	737.97
	- Potable Spirits	-	-	290.43	-	290.43	326.53
	- Ennature Biopharma	-	-	77.90	-	77.90	92.49
	- Bio-Fuel	-	-	82.42	-	82.42	92.27
	- Unallocated	-	-	2,624.63	-	2,624.63	2,340.91
	Total	**1,353.24**	**1,274.85**	**3,763.61**	**1,353.24**	**3,763.61**	**3,590.17**

Notes:

1 The above results were reviewed by the Audit committee in its meeting held on November 13, 2026 and have been approved by the Board of Directors in its meeting held on November 13, 2026. The auditors of the Company have carried out a limited review of the same.

2 Financial results have been prepared and presented in accordance with the recognition and measurement principles prescribed under Section 133 of the Companies Act, 2013.

3 The Hon'ble National Company Law Tribunal, Allahabad Bench, Prayagraj ("NCLT"), vide its order dated July 17, 2026, has approved the Scheme of Arrangement ("Scheme") among India Glycols Limited (Demerged Company) and IGL Spirits Limited (Resulting Company 1) and Ennature Bio Pharma Limited (Resulting Company 2) and their respective shareholders and creditors for the demerger of the Spirits and Biofuel Undertaking and Biopharma Undertaking into IGL Spirits Limited and Ennature Bio Pharma Limited respectively. The Scheme became effective on September 01, 2026 with the appointed date 01st April 2026.
(i) Spirits and Biofuel undertaking and Biopharma Undertaking of India Glycols Limited has been demerged and vested in IGL Spirits Limited and Ennature Biopharma Limited respectively as a going concern w.e.f. the appointed date of April 1, 2026, as per the Scheme.
(ii) All the carrying value of assets, liabilities and identified reserves of the Spirits and Biofuel undertaking and Biopharma Undertaking have been transferred to the Resulting Companies. The difference between the value of transferred assets, liabilities and identified reserves pertaining to the Spirits and Biofuel undertaking and Biopharma Undertaking has been adjusted in the other equity as per the applicable laws.
(iii) Accordingly, the financial results of the Company for the quarter ended June 30, 2026 and the quarter and the six months ended September 30, 2026, do not include the financial performance of the Spirits and Biofuel undertaking and Biopharma Undertaking of the Company and restated the figures for the quarter ended 30th June 2026..
(iv) The comparative figures for the quarter and six months ended 30 September 2025 and the year ended 31 March 2026 include the Spirits and Biofuel Undertaking and Biopharma Undertaking, which have been demerged from the Company with effect from 1 April 2026 pursuant to the Scheme of Arrangement. Accordingly, such comparative figures are not comparable with the corresponding current-period figures/six months figures.
(v) All sales and purchases of Spirits & Biofuel and Biopharma businesses continue to be accounted in the books of account of India Glycols Limited but transferred to the respective resulting companies as provided in the aforesaid scheme approved.

4 The parent company has identified its business operations as a single reportable segment, namely 'Bio-based Specialties and Performance Chemicals', in accordance with the requirements of Ind AS 108 – Operating Segments. Accordingly, no separate segment information has been provided for the current period.

5 The figures of the previous period/year have been restated/regrouped wherever necessary, to make them comparable.

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

For INDIA GLYCOLS LIMITED

U.S. BHARTIA
Chairman and Managing Director
DIN: 00063091

Place : Noida
Date : 13th November , 2026

Statement of Consolidated Cash Flows

(₹ In Crores)

	Particulars	Consolidated Half Year ended 30.09.2026 (Unaudited)	Consolidated Half Year ended 30.09.2025 (Unaudited)
A.	**Cash Flow from Operating Activities**		
	Net Profit/(Loss) Before Tax	**31.24**	**143.96**
	Adjustments For:		
	Depreciation and amortisation expense	24.05	72.93
	(Profit)/Loss on Sale of Property, plant & equipment	(0.01)	(0.75)
	Net Unrealised Foreign Exchange Fluctuation (Gain) / Loss	(2.86)	8.31
	Govt Grant (net)	-	(0.06)
	Provision No Longer Required Written Back	(0.71)	(0.02)
	Finance Costs	23.71	94.23
	Interest Income	(0.70)	(2.86)
	Operating Profit/ (Loss) before Working Capital Changes	**74.72**	**315.74**
	Adjustments For:		
	(Increase)/Decrease in Trade & Other Receivables	(4.44)	59.58
	(Increase)/Decrease in Inventories	51.86	87.41
	Increase / (Decrease) in Trade & Other Payables	(72.38)	(343.79)
	Cash Generated from / (Used in) Operations	**49.76**	**118.94**
	Income Tax Paid (Net)	(10.45)	(12.59)
	Net Cash flow from / (Used in) Operating Activities	**39.31**	**106.35**
B.	**Cash Flow from Investing Activities**		
	Purchase of Property, plant & equipment	(95.23)	(165.11)
	Interest received	0.70	6.07
	Net Cash flow from / (Used in) Investing Activities	**(94.53)**	**(159.04)**
C.	**Cash Flow from Financing Activities**		
	Net Proceeds from Borrowings	58.26	169.18
	Payment of lease liabilities	-	(9.90)
	Finance Costs	(23.71)	(95.33)
	Dividends Paid	-	(0.23)
	Net Cash flow from / (Used in) Financing Activities	**34.55**	**63.72**
	Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	**(20.67)**	**11.03**
	Opening Cash & Cash Equivalent	**27.16**	**6.84**
	Closing Cash & Cash Equivalent	**6.49**	**17.87**

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard -7, "Statement of Cash Flows".

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

Statement of Consolidated Assets and Liabilities

(₹ In Crores)

	Particulars	Consolidated	
		As At	
		30.09.2026 (Unaudited)	31.03.2026 (Audited)
A.	**ASSETS**		
1	**Non-current Assets**		
	(a) Property, Plant and Equipment	1,254.43	4,445.21
	(b) Capital work-in-progress	113.52	36.70
	(c) Investment Property	1.70	1.72
	(d) Other Intangible assets	0.68	1.46
	(e) Right to use assets	-	106.08
	(f) Investments in Joint Venture	422.17	388.79
	(g) Financial Assets	-	
	(i) Loans	1.18	1.50
	(ii) Others	35.83	41.08
	(h) Other non-current assets	2.69	2.60
	Total Non Current Assets	**1,832.20**	**5,025.14**
2	**Current Assets**		
	(a) Inventories	553.70	890.61
	(b) Financial Assets	-	
	(i) Trade receivables	76.22	351.40
	(ii) Cash and cash equivalents	6.49	31.87
	(iii) Bank balances other than (ii) above	8.78	17.96
	(v) Others	40.88	39.10
	(c) Current Tax Assets (Net)	18.51	12.08
	(d) Other current assets	74.24	154.79
	Total Current Assets	**778.82**	**1,497.81**
	Total Assets	**2,611.02**	**6,522.95**
B.	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	33.51	33.51
	(b) Other Equity	1,224.27	2,899.27
	Total Equity	**1,257.78**	**2,932.78**
2	**Liabilities**		
2.1	**Non-current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	341.48	919.13
	(ii) Lease Liabilities	-	81.13
	(iii) Other financial liabilities	-	62.29
	(b) Provisions	2.91	5.68
	(c) Deferred tax liabilities (Net)	151.17	505.11
	(d) Others	-	2.72
	Total Non-current Liabilities	**495.56**	**1,576.06**
2.2	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	484.49	659.34
	(ii) Lease Liabilities	-	31.01
	(iii) Trade payables	-	
	total outstanding dues of micro enterprises and small enterprises	-	0.17
	total outstanding dues of creditors other than micro enterprises and smal enterprises	55.34	787.71
	(iii) Other financial liabilities	276.16	401.03
	(b) Other current liabilities	37.28	127.29
	(c) Provisions	4.41	7.56
	Total Current Liabilities	**857.68**	**2,014.11**
	Total Equity and Liabilities	**2,611.02**	**6,522.95**

Note : Assets & Liabilities as on 31 March 2026 include combined results of Spirits & Biofuel and Biopharma businesses.

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of India Glycols Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of India Glycols Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results ('the Statement') of **India Glycols Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its share of the net Profit after tax and total comprehensive Income of its joint venture for the quarter ended 30th September, 2026 and year to date results for the period from 1st April 2026 to 30th September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

5. The Statement includes the results of the following entities:

Subsidiaries

i) IGL Finance Limited
ii) IGL Chem International Pte. Ltd., Singapore
iii) IGL Chem International USA LLC
iv) IGL Chemicals and Services Private Limited

Joint Venture

i) Clariant IGL Specialty Chemicals Private Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above and upon consideration of the review report of other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We draw attention to note 3 to the statement with respect to the Scheme of Arrangement ("Scheme") duly approved by the Hon'ble National Company Law Tribunal, Allahabad Bench, Prayagraj ("NCLT"). The Spirits and Biofuel undertaking and Biopharma undertaking of the Holding Company stands demerged and vested in IGL Spirits Limited and Ennature Bio Pharma Limited respectively w.e.f. April 1, 2026, being the appointed date. Consequently, the results for the quarter ended June 30, 2026, which was subject to limited review by us as required under the Listing Regulations, have been restated to give effect to the demerger. The demerger has been accounted w.e.f. the appointed date i.e. April 1, 2026, in accordance with the accounting treatment specified in the Scheme. Further, IGL Spirits Limited and Ennature Bio Pharma Limited cease to be the subsidiary of the Company with effect from the appointed date.

8. The consolidated unaudited financial results include the Group's share of net profit after tax of ₹ 12.64 crore and ₹ 33.24 crore and total comprehensive income of ₹ 12.75 crore and ₹ 33.38 crore for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, as considered in the Statement, in respect of a joint venture, whose interim financial information / financial result has not been reviewed by us. This interim financial information/ financial result has been reviewed by another auditor whose report has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this joint venture, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 and 4 above.

   Our conclusion on the Statement is not modified in respect of this matter.

For **K N GUTGUTIA & CO.**
Chartered Accountants
Firm's Registration No. 304153E

(B.R. GOYAL)
Partner
Membership No. 012172
UDIN: 26012172VEUXNI2894



Date: 13th November 2026
Place of Signature: Noida